Deferasirox-d4, CAS 1133425-75-8

Formulation: A solid

Formal Name: 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic-2,3,5,6-d4 acid

Purity: ≥99% deuterated forms (d1-d4)

Formula Markup: C21H11D4N3O4

Formula Weight: 377,4

Shelf life (days): 1460

CAS Number: 1133425-75-8

Notes: Deferasirox-d4 is intended for use as an internal standard for the quantification of deferasirox (Item No. 16753) by GC- or LC-MS. Deferasirox is a synthetic, tridentate iron chelator that binds iron at a 2:1 ratio.{36858} It is selective for iron (Fe(III)) over Cu(II), Zn(II), Mg(II), and Ca(II) but does bind to Al(III). Deferasirox decreases iron levels in iron-loaded rat heart cells in vitro by 45.8 and 55.6% compared to control levels when used at concentrations of 160 and 320 µM, respectively.{27434} In hypertransfused rats, deferasirox (200 mg/kg) decreases radiolabeled liver iron levels from 41 to 21.7% and blood iron levels from 8.2 to 3.4%.{27434} It is primarily excreted via the fecal route, in contrast to the iron chelator deferoxamine (Item No. 14595).{27434} Deferasirox also inhibits proliferation of SAS human oral squamous carcinoma cells (EC50 = 21 µM), decreases cyclin D1 protein levels, and increases protein levels of N-Myc downregulated gene 1 (NDRG1) and NDRG3.{38960} It acts in a synergistic manner when used in combination with gemcitabine (Item Nos. 11690 / 9003096) to reduce proliferation of BxPC-3 pancreatic cancer cells in vitro and reduce tumor growth in a BxPC-3 mouse xenograft model when administered at a dose of 200 mg/kg.{36859} Formulations containing deferasirox have been used in the treatment of β-thalassemia and chronic iron overload.

• Artikelnummer: CAY25430-1
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 25430-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Methode: GC-MS, LC-MS, Isotopenmarkierung